A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Overview[ - collapse ][ - ]
| Purpose | Objectives: To prove non-inferiority of Targin compared to Oxycontin in terms of reduction of pain intensity 1. Primary objective: Actual reduction of pain intensity (0-10) score (average pain over 24 hours obtained each evening) within 4 weeks 2. Secondary objectives: Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events, Long term safety and efficacy |
|---|---|
| Condition | Cancer |
| Intervention | Drug: oxycodone and naloxone |
| Phase | Phase 4 |
| Sponsor | Mundipharma Pte Ltd. |
| Responsible Party | Mundipharma Pte Ltd. |
| ClinicalTrials.gov Identifier | NCT01313780 |
| First Received | March 8, 2011 |
| Last Updated | March 13, 2013 |
| Last verified | March 2013 |
Tracking Information[ + expand ][ + ]
| First Received Date | March 8, 2011 |
|---|---|
| Last Updated Date | March 13, 2013 |
| Start Date | May 2011 |
| Estimated Primary Completion Date | July 2013 |
| Current Primary Outcome Measures | Assess reduction of pain intensity [Time Frame: NRS will be captured at 4 weeks] [Designated as safety issue: No]Actual reduction of pain intensity (0-10) score (average pain over 24 hours obtained each evening) within 4 weeks through measuring pain intensity with NRS (Numeric Rating Scale). |
| Current Secondary Outcome Measures | Efficacy parameters including long term safety and efficacy [Time Frame: They will be assessed at 4 weeks] [Designated as safety issue: Yes]Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events, Long term safety and efficacy |
Descriptive Information[ + expand ][ + ]
| Brief Title | A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients |
|---|---|
| Official Title | A 4-week Multicentre, Randomized, Open Label, Parallel Group, Active Control Phase IV Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone in Comparison With Oxycontin in Korean Patients With Cancer Pain(TOP) |
| Brief Summary | Objectives: To prove non-inferiority of Targin compared to Oxycontin in terms of reduction of pain intensity 1. Primary objective: Actual reduction of pain intensity (0-10) score (average pain over 24 hours obtained each evening) within 4 weeks 2. Secondary objectives: Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events, Long term safety and efficacy |
| Detailed Description | This will be a 4-week multicentre, randomized, open label, parallel group, active control study to evaluate efficacy and safety of Targin in comparison with Oxycontin in Korean patients with cancer pain who are administered weak opioid or naïve patients including patient not on the long term strong opioid medication within 3 months. |
| Study Type | Interventional |
| Study Phase | Phase 4 |
| Study Design | Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Cancer |
| Intervention | Drug: oxycodone and naloxone Trade name is TARGIN. Oxycodone (10mg)/naloxone(5mg) or Oxycodone(20mg)/naloxone(10mg) tablets provided in 56-tablet box. Twice daily per oral Other Names:
|
| Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Recruiting |
|---|---|
| Estimated Enrollment | 128 |
| Estimated Completion Date | July 2013 |
| Estimated Primary Completion Date | April 2013 |
| Eligibility Criteria | Inclusion Criteria: 1. Male or female cancer patients 20 years of age or older 2. Cancer related pain that requires treatment with continuous around-the-clock strong opioid analgesic 3. Moderate to severe pain intensity(NRS pain score 4) 4. Opioid naïve patients or patients not treated with strong opioids(except PRN) within 4 weeks or patients who has been on weak opioids 5. Subject who provide signed and dated written voluntary informed consent Exclusion Criteria: 1. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are: - women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner - women shoes partners have been sterilized by vasectomy or other means - two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent. 2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test. 3. Have previously received treatment with Targin or Oxycontin within 4weeks(28days) of screening periods(including PRN) 4. If subjects started first cycle of chemotherapy during the 2 weeks before the screening visit or during the study, they should be excluded from the study. And If the chemotherapy regimen or dosage to be planned to change during the study, the subjects should be excluded from the study. 5. Patient who is administered laxatives with stable dose for more than 1 week 6. Patient with evidence of significant structural/functional abnormalities of GI tract which is not appropriate for oral medicine administration. Any history of hypersensitivity to Oxycodone and Naloxone 7. Patients with significant respiratory depression 8. Patients with acute or severe bronchial asthma or hypercarbia 9. Any patient who has or is suspected of having paralytic ileus 10. Severe Chronic obstructive pulmonary disease, pulmonary heart disease 11. Targin product contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take 12. Patients with moderate and severe hepatic impairment 13. Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (>2.5 times the upper limit of normal, it is allowed >5 times the upper limit of normal in case of transition in liver) or an abnormal total bilirubin and/or creatinine level(s) (greater than 1.5 times the upper limit of normal) 14. Any situation where opioids are contraindicated 15. Major surgery within 1 month prior to screening or planned surgery 16. Mainly pain originated other than cancer or cancer related conditions (eg. Musculoskeletal pain, inflammatory pain, diabetic polyneuropathy) 17. Patients with known or suspected unstable brain metastases or spinal cord compression that may require changes in steroid treatment throughout the duration of the study 18. Patients with uncontrolled seizures 19. Requiring interventional treatment for pain such as neurodestructive procedure or regional infusion 20. With a history of alcohol abuse within 6 months of screening 21. With a history of illicit drug abuse within 6 months of screening 22. Patients with increased intracranial pressure 23. In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication 24. Patients with myxodema, not adequately treated hypothyroidism or Addison's disease 25. Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine) 26. Patients with evidence of clinically significant gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related to the underlying cancer or disease progression 27. Patients suffering from diarrhea and/or opioid withdrawal 28. With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score 29. Clinically significant impairment of cardiovascular, respiratory and renal function 30. Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment 31. Having used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer |
| Gender | Both |
| Ages | 20 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Contact: Mundipharma Korea Ltd. +82 2 527 9218 Kr_Med@mundipharma.co.kr |
| Location Countries | Korea, Republic of |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT01313780 |
|---|---|
| Other Study ID Numbers | OXN10-KR-002 |
| Has Data Monitoring Committee | No |
| Information Provided By | Mundipharma Pte Ltd. |
| Study Sponsor | Mundipharma Pte Ltd. |
| Collaborators | Not Provided |
| Investigators | Principal Investigator: Kim, M.D Asan Medical CenterPrincipal Investigator: Ahn, M.D Samsung Medical CenterPrincipal Investigator: Kim, M.D National Cancer CenterPrincipal Investigator: Kim, M.D SMG-SNU Boramae Medical CenterPrincipal Investigator: Lee, M.D Shinchone Yonsei Severance Medical CenterPrincipal Investigator: Kang Jugnhoon Kyungsang University HospitalPrincipal Investigator: Lee Kyunghee, MD Youngnam Univ. HospitalPrincipal Investigator: Yoon Hwanjung, MD Chungnam University Hospital |
| Verification Date | March 2013 |
Locations[ + expand ][ + ]
| AMC | Seoul, Pungnap-dong, Korea, Republic of, 138-736 Contact: Seonhwa Kim, NursePrincipal Investigator: Mundipharma Korea Ltd. Recruiting |
|---|---|
| Investigational Site | Seoul, Korea, Republic of Contact: Mundipharma Korea Ltd.Principal Investigator: Mundipharma Korea Ltd. Not yet recruiting |